<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00714649</url>
  </required_header>
  <id_info>
    <org_study_id>CHIRON 2008-01</org_study_id>
    <nct_id>NCT00714649</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Cetuximab in HNSCC Combined With Curative Surgery</brief_title>
  <acronym>CHIRON</acronym>
  <official_title>Neoadjuvant Cetuximab Monotherapy Followed by Surgery in Squamous Cell Carcinoma of Head and Neck: Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Serono International SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary diagnose HNSCC carcinoma patients eligible for curative surgery will be proposed the&#xD;
      addition of 2 or 3 neoadjuvant cetuximab infusions. The main objective is to reduce to a&#xD;
      minimal delay the time elapsing between last infusion and surgery.&#xD;
&#xD;
      Iterative biomarkers will be taken at 6 time points permitting to investigate expression gen&#xD;
      profile and protein mutation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I/II trial of neoadjuvant cetuximab monotherapy in the preoperative treatment&#xD;
      of patients with operable HNSCC. It is a monocenter study (St-Luc university Hospital,&#xD;
      Université catholique de Louvain, Brussels).&#xD;
&#xD;
      This part of the trial will determine the safe minimum delay between the neoadjuvant&#xD;
      cetuximab infusion and surgery. The aim is to investigate if cetuximab given 24 hours before&#xD;
      surgery is safe.&#xD;
&#xD;
      Patients will receive cetuximab with a loading dose of 400 mg/m2 for the first administration&#xD;
      followed by 250 mg/m2/week at the second and third administrations, if applicable. The delay&#xD;
      between the last administration of cetuximab and surgery will be progressively reduced&#xD;
      (Figure 1).&#xD;
&#xD;
      Five levels are pre-defined before final administration of 3 preoperative doses of cetuximab&#xD;
      with a 24-hour delay between the last dose of cetuximab and surgery.&#xD;
&#xD;
      Level I: 10-12 days delay between the second cetuximab infusion and surgery (total of 2 doses&#xD;
      pre-op) Level II: 6-8 days delay between the second cetuximab infusion and surgery (total of&#xD;
      2 doses pre-op) Level III: 3-4 days delay between the second cetuximab infusion and surgery&#xD;
      (total of 2 doses pre-op) Level IV: 3-4 days delay between the third cetuximab infusion and&#xD;
      surgery (total of 3 doses pre-op) Level V: 24-hour delay between the third cetuximab dose and&#xD;
      surgery (total of 3 doses pre-op) The cohort size is 3 patients per level, extended to 6&#xD;
      patients if one &quot;limiting toxicity&quot; is observed. Decision rules are the same than as in any&#xD;
      classic 3+3 phase 1design (Figure 2).&#xD;
&#xD;
      &quot;Limiting toxicity&quot; is defined as (i) any life-threatening (grade 4) surgical complication or&#xD;
      (ii) an unexpected surgical grade 3 toxicity. Unexpected toxicity will be determined by the&#xD;
      safety committee after careful review of the patient file.&#xD;
&#xD;
      The safety committee will consist of the surgical team of UCL Saint-Luc, one external&#xD;
      surgeon, one representative from Merck and the study coordinators.&#xD;
&#xD;
      Patients treated at level V will be evaluated like patients in the phase II part.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the safety administration of cetuximab - Phase 1: to determine the safe minimum delay between preoperative cetuximab infusion and surgery -Phase II: to investigate the safety of the minimum delay determined in the phase I part.</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the safety of postoperative radiation therapy in combination with cetuximab</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the efficacy of cetuximab monotherapy in the pre-operative setting, using FDG-PET and PET/CT scan.</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To perform translational research</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>I-1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This is a phase I/II trial. PhaseI: The delay between the last administration of cetuximab and surgery will be progressively reduced. Five delay schedules are pre-defined before final administration of 3 preoperative doses of cetuximab with a 24-hour delay between the last dose of cetuximab and surgery. The cohort size is 3 patients per delay schedule, extended to 6 patients if one &quot;limiting toxicity&quot; is observed.&#xD;
Phase II: will proceed if delay schedule V is safe. The patients included in delay schedule V of the Phase I part of the study will be involved in the phase II analysis. Recruitment of a total of 12 patients (3-6 of delay schedule V in phase I plus an additional 3-9 patients).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Cetuximab 250mg/m²/week IV before surgery till surgery</description>
    <arm_group_label>I-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  More than 18 years&#xD;
&#xD;
          -  Histologically proven squamous cell carcinoma of the oral cavity, oropharynx,&#xD;
             hypopharynx or larynx&#xD;
&#xD;
          -  patients selected for a primary surgical treatment&#xD;
&#xD;
          -  No distant metastases&#xD;
&#xD;
          -  No active second malignancy during the last 5 years&#xD;
&#xD;
          -  No prior or concurrent evidence of uncontrolled severe pathology precluding&#xD;
             administration of surgery&#xD;
&#xD;
          -  life expectancy more than 3 months&#xD;
&#xD;
          -  Not pregnant or nursing; fertile patients both male or female, must use effective&#xD;
             contraception&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Performance Status ECOG 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Nasopharynx cancer&#xD;
&#xD;
          -  Past or current malignancy other than HNSCC&#xD;
&#xD;
          -  performance Status ECOG above 2&#xD;
&#xD;
          -  Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not&#xD;
             indicated in the study protocol&#xD;
&#xD;
          -  Use of any investigationals agents within 4 weeks prior ti entry&#xD;
&#xD;
          -  Previous exposure to EGFR targeting therapy&#xD;
&#xD;
          -  Known grade hypersensitivity to cetuximab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pascal H Machiels, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires St Luc-UCL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires St Luc-UCL</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>July 8, 2008</study_first_submitted>
  <study_first_submitted_qc>July 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2008</study_first_posted>
  <last_update_submitted>November 13, 2012</last_update_submitted>
  <last_update_submitted_qc>November 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and Neck Squamous Cell Carcinoma treated with surgery</keyword>
  <keyword>and/or radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

